{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:41:25Z","timestamp":1794559285702,"version":"4.9.1"},"reference-count":47,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T00:00:00Z","timestamp":1774569600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jacadv.2026.102765","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T20:59:08Z","timestamp":1776891548000},"page":"102765","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease"],"prefix":"10.1016","volume":"5","author":[{"given":"Alexander T.","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Furst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-0723","authenticated-orcid":false,"given":"Fatima","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"J. Maron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1256-5741","authenticated-orcid":false,"given":"Shriram","family":"Nallamshetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Din","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Zitko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kat","family":"Khachatourian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8768-1990","authenticated-orcid":false,"given":"Ivy","family":"Tonnu-Mihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacadv.2026.102765_bib2","article-title":"Estimated number and percentage of US adults with atherosclerotic cardiovascular disease recommended add-on lipid-lowering therapy by the 2018 AHA\/ACC multi-society cholesterol guideline","volume":"21","author":"Alanaeme","year":"2022","journal-title":"Am Heart J Plus"},{"issue":"20","key":"10.1016\/j.jacadv.2026.102765_bib3","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1161\/CIR.0000000000001184","article-title":"Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000504558","article-title":"Impact of cardio-renal-metabolic comorbidities on cardiovascular outcomes and mortality in type 2 diabetes mellitus","volume":"51","author":"Cherney","year":"2020","journal-title":"Am J Nephrol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib5","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-66655-0","article-title":"Impact of chronic kidney disease and end-stage renal disease on the mid-term adverse outcomes in diabetic patients with cardiovascular diseases","volume":"14","author":"Chou","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacadv.2026.102765_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajpc.2025.100950","article-title":"Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS)","volume":"21","author":"Lv","year":"2025","journal-title":"Am J Prev Cardiol"},{"issue":"9709","key":"10.1016\/j.jacadv.2026.102765_bib7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","author":"Kaptoge","year":"2010","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12881-019-0910-z","article-title":"Association of high sensitive C-reactive protein with coronary heart disease: a Mendelian randomization study","volume":"20","author":"Zhuang","year":"2019","journal-title":"BMC Med Genet"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102765_bib9","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005610","article-title":"Cumulative exposure to high-sensitivity C-Reactive protein predicts the risk of cardiovascular disease","volume":"6","author":"Wang","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1161\/CIRCULATIONAHA.123.066213","article-title":"CLEAR outcomes investigators. Inflammation and cholesterol as predictors of cardiovascular events among 13 970 contemporary high-risk patients with statin intolerance","volume":"149","author":"Ridker","year":"2024","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102765_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102765_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.123.030131","article-title":"Albuminuria: an underappreciated risk factor for cardiovascular disease","volume":"13","author":"Barzilay","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102765_bib13","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-Reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102765_bib14","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-Reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102765_bib15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jech-2019-213289","article-title":"Association between C reactive protein and all-cause mortality in the ELSA-Brasil cohort","volume":"74","author":"Maluf","year":"2020","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102765_bib16","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.ahj.2015.04.017","article-title":"Six-year change in high-sensitivity C-reactive protein and risk of diabetes, cardiovascular disease, and mortality","volume":"170","author":"Parrinello","year":"2015","journal-title":"Am Heart J"},{"issue":"24","key":"10.1016\/j.jacadv.2026.102765_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016502","article-title":"Association of diagnostic coding-based frailty and outcomes in patients with heart failure: a report from the veterans affairs health system","volume":"9","author":"Kohsaka","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102765_bib19","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using International classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1475-6773.2012.01440.x","article-title":"Case definitions for acute myocardial infarction in administrative databases and their impact on In-Hospital mortality rates","volume":"48","author":"Metcalfe","year":"2013","journal-title":"Health Serv Res"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102765_bib21","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004966","article-title":"Comparison of expert adjudicated coronary heart disease and cardiovascular disease mortality with the National death index: results from the REasons for geographic and racial differences in stroke (REGARDS) study","volume":"6","author":"Olubowale","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102765_bib22","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.7326\/0003-4819-129-12-199812150-00005","article-title":"Accuracy of death certificates for coding coronary heart disease as the cause of death","volume":"129","author":"Lloyd-Jones","year":"1998","journal-title":"Ann Intern Med"},{"issue":"3 Suppl","key":"10.1016\/j.jacadv.2026.102765_bib23","doi-asserted-by":"crossref","first-page":"15S","DOI":"10.1177\/1077558703256485","article-title":"Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA","volume":"60","author":"Wagner","year":"2003","journal-title":"Med Care Res Rev"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102765_bib25","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2020.1267","article-title":"Why test for proportional hazards?","volume":"323","author":"Stensrud","year":"2020","journal-title":"JAMA"},{"issue":"27","key":"10.1016\/j.jacadv.2026.102765_bib26","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting fine-gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.jacadv.2026.102765_bib27","article-title":"The missing covariate indicator method is nearly valid almost always","author":"Xu","year":"2021","journal-title":"Preprint"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102765_bib28","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.amjcard.2008.07.060","article-title":"The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years","volume":"102","author":"Rashidi","year":"2008","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102765_bib29","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jacc.2006.05.047","article-title":"Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction","volume":"48","author":"Wattanakit","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0735-1097(02)02663-3","article-title":"Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community","volume":"41","author":"Manjunath","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102765_bib31","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1053\/j.ajkd.2004.04.024","article-title":"Kidney disease as a risk factor for recurrent cardiovascular disease and mortality","volume":"44","author":"Weiner","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"10.1016\/j.jacadv.2026.102765_bib32","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMoa041365","article-title":"Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction","volume":"351","author":"Anavekar","year":"2004","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102765_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1475-6773.2011.01242.x","article-title":"Following the money: factors associated with the cost of treating high-cost medicare beneficiaries","volume":"46","author":"Reschovsky","year":"2011","journal-title":"Health Serv Res"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102765_bib34","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1001\/jama.2015.8035","article-title":"Mortality, hospitalizations, and expenditures for the medicare population age 65 and older, 1999\u20132013","volume":"314","author":"Krumholz","year":"2015","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102765_bib35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"issue":"44","key":"10.1016\/j.jacadv.2026.102765_bib36","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","article-title":"Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease","volume":"45","author":"Mazhar","year":"2024","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102765_bib37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa042378","article-title":"Pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) investigators. C-reactive protein levels and outcomes after statin therapy","volume":"352","author":"Ridker","year":"2005","journal-title":"N Engl J Med"},{"issue":"10384","key":"10.1016\/j.jacadv.2026.102765_bib38","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(23)00215-5","article-title":"Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials","volume":"401","author":"Ridker","year":"2023","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jacadv.2026.102765_bib39","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102765_bib40","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"36","key":"10.1016\/j.jacadv.2026.102765_bib41","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102765_bib42","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/2047487319846715","volume":"26","author":"Rossello","year":"2019","journal-title":"Eur J Prev Cardiol"},{"issue":"18","key":"10.1016\/j.jacadv.2026.102765_bib43","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/eurheartj\/ehac056","article-title":"Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm","volume":"43","author":"Hageman","year":"2022","journal-title":"European Heart Journal"},{"issue":"14","key":"10.1016\/j.jacadv.2026.102765_bib44","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/j.jacc.2022.07.006","article-title":"2022 ACC expert consensus decision pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology solution set oversight committee","volume":"80","author":"Lloyd-Jones","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacadv.2026.102765_bib45","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.jacadv.2026.102765_bib46","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.jacadv.2026.102765_bib47","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jacadv.2026.102765_bib48","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa2405922","article-title":"Colchicine in acute myocardial infarction","volume":"392","author":"Jolly","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102765_bib49","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/s44161-024-00600-2","article-title":"Implications and limitations of the CLEAR-SYNERGY trial for the use of low-dose colchicine in cardiovascular disease","volume":"4","author":"Misra","year":"2025","journal-title":"Nat Cardiovasc Res"},{"issue":"10289","key":"10.1016\/j.jacadv.2026.102765_bib50","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","article-title":"IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"397","author":"Ridker","year":"2021","journal-title":"Lancet (London, England)"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:55:59Z","timestamp":1793922959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":47,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2772963X26001869"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102765","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102765","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102765"}}